Conflict of Interest: None.
Multilocus Analyses Reveal Involvement of the ESR1, ESR2, and FSHR Genes in Migraine
Article first published online: 29 OCT 2008
© 2008 the Authors. Journal compilation © 2008 American Headache Society
Headache: The Journal of Head and Face Pain
Volume 48, Issue 10, pages 1438–1450, November/December 2008
How to Cite
Oterino, A., Toriello, M., Cayón, A., Castillo, J., Colas, R., Alonson-Arranz, A., Ruiz-Alegria, C., Quintela, E., Monton, F., Ruiz-Lavilla, N., Gonzalez, F. and Pascual, J. (2008), Multilocus Analyses Reveal Involvement of the ESR1, ESR2, and FSHR Genes in Migraine. Headache: The Journal of Head and Face Pain, 48: 1438–1450. doi: 10.1111/j.1526-4610.2008.01294.x
- Issue published online: 19 NOV 2008
- Article first published online: 29 OCT 2008
- Accepted for publication May 9, 2008
- estrogen receptor 1;
- estrogen receptor 2;
- follicle stimulating hormone receptor;
- genetic association
Objective.— Female hormone genes have been investigated in migraine in recent years. Research in this field has been controversial, especially in regard to ESR1 gene findings. None of the reports have yet to approach the problem from a multigenic point of view.
Methods.— We investigated 5 polymorphisms implicated in female hormone metabolism (FSHR, CYP19A1, ESR1, NRIP1, and ESR2) in a cohort of 730 subjects matched for age and sex. The effect of gene–gene interaction was assessed using the set association approach, and the corresponding haplotypes were studied with PM Plus software. To corroborate initial results, we analyzed the selected markers using a cohort of 134 families in which 168 trios were suitable for transmission-disequilibrium test (TDT) analysis under the migraine with aura (MA) phenotype.
Results.— A total of 356 consecutive migraine patients (198 with MA [76% females] and 158 migraine without aura [MO, 74% females], and 374 matched controls [71% females]) were genotyped. In the 2-point analyses, the ESR1 and ESR2 polymorphisms showed nominal association under MA/MO phenotype, and this association was higher with the FSHR polymorphism in MA females (P = .004, uncorrected). Using the SUMSTAT program, we observed ESR2-ESR1-FSHR significant gene–gene interaction, suggesting association with the MA/MO phenotype (P = .005; P = .003 in females), and with MA alone (P = .021; P = .030 for females). We corroborated that ESR2-ESR1-FSHR haplotypes interacted for migraine under a model-free hypothesis (empirical P = .010 for the whole sample; P = .001 for females), and the association was stronger for the MA phenotype alone (empirical P = 5.0e-4, under the heterogeneity model; P = .001 for females). These results were corroborated using family-based association approaches. We observed nominal association for ESR2 and ESR1 (P = .031 and .034, respectively) in the TDT study, and significant association for ESR1 using family-based association test statistics. Haplotype-TDT analyses showed further significant gene–gene interaction for ESR1-ESR2 (global P = .009), ESR2-FSHR (global P = .011), and nominally significant interaction for ESR2-ESR1-FSHR genes (global P = .037).
Conclusion.— We found significant association of female hormone metabolism polymorphisms under the perspective of multigene approach.